Yanli Xu
68 Changle Road
Nanjing, 210006, China
Nanjing, 210006, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 16 publications
Nintedanib is a potent FLT3 inhibitor with activity against FLT3-ITD and overcomes the gatekeeper F691L resistance mutation in acute myeloid leukemia.
Journal: European journal of pharmacology
Published: January 05, 2026
Unit-Emitting Carbon Dots.
Journal: The journal of physical chemistry letters
Published: June 13, 2024
Ningetinib, a novel FLT3 inhibitor, overcomes secondary drug resistance in acute myeloid leukemia.
Journal: Cell communication and signaling : CCS
Published: April 17, 2024
Foretinib Is Effective in Acute Myeloid Leukemia by Inhibiting FLT3 and Overcoming Secondary Mutations That Drive Resistance to Quizartinib and Gilteritinib.
Journal: Cancer research
Published: July 05, 2023
Eltrombopag modulates the phenotypic evolution and potential immunomodulatory roles of monocytes/macrophages in immune thrombocytopenia.
Journal: Platelets
Published: October 25, 2022
Combined multiomics analysis reveals the mechanism of CENPF overexpression-mediated immune dysfunction in diffuse large B-cell lymphoma in vitro.
Journal: Frontiers in genetics
Published: October 17, 2022
Characteristics of macrophages from myelodysplastic syndrome microenvironment.
Journal: Experimental cell research
Published: July 12, 2021
The iron chelator deferoxamine decreases myeloma cell survival.
Journal: The Journal of international medical research
Published: January 22, 2021
Effects of Deferoxamine on Leukemia In Vitro and Its Related Mechanism.
Journal: Medical science monitor : international medical journal of experimental and clinical research
Published: September 25, 2018
A rare case of multicentric castleman's disease transforms into multiple myeloma and its successful treatment.
Journal: Cancer biology & therapy
Published: March 28, 2018
Last Updated: 09/26/2026